Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02527187
Other study ID # T502-SSP-007
Secondary ID 2013-005368-24
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2015
Est. completion date November 2016

Study information

Verified date May 2022
Source Inmunotek S.L.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective is to evaluate the concentration of allergen extract of Betula verrucosa that elicit a papule equivalent to that produced by a solution of histamine dihydrochloride 10 mg / ml in size.


Description:

Open, prospective, unblinded and non-randomized biological assay. Each patient was tested with four concentrations of allergen and with a histamine and saline solution as positive and negative controls, respectively.


Recruitment information / eligibility

Status Completed
Enrollment 201
Est. completion date November 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender All
Age group 5 Years to 70 Years
Eligibility General inclusion criteria for both groups: - Positive skin prick test with the positive control (Histamine HCl at 10 mg/mL). The length of the largest diameter of the wheal induced by this control should be = 3 mm. - Negative skin prick test with the negative control. The length of the largest diameter of the wheal induced by this control should be < 3 mm. - All ages and both genders. For the group of patients CH+ (true positive to Betula verrucosa): All these patients had a previous diagnosis of allergy to the birch pollen: - A positive case history with inhalant allergy related to exposure to birch pollen. - A positive skin prick test (mean wheal diameter = 3 mm) when tested with a biologically standardized extract prepared from birch pollen. This preparation, from another manufacturer, was the one used in the routine in the Hospital. - Positive test for specific IgE (CAP value > 0.35 IU/mL). For the group of patients CH- (true negative to Betula verrucosa): All these patients had a previous diagnosis of allergy to agents unrelated to birch pollen. - A negative case history with inhalant allergy related to exposure to birch pollen or to pollen with known cross-reactivity with the birch pollen. These patients could be allergic to other pollen or other allergens, such mites. - A negative prick test (largest diameter of the wheal = 3 mm) when tested with a standardized extract prepared from the allergen source in question. - A negative test for specific IgE (CAP value < 0.35 IU/mL) to birch pollen or to pollen with known cross-reactivity with birch pollen: Corylus avellana, Quercus verrucosa, Fagus sylvatica, Castanea satavia, Carpinus betelus and Alnus glutinosa. Exclusion criteria for both groups: - Patients that were using drugs that may interfere with the skin prick tests. - Patients using the following drugs 24 hours before the test: theophylline, systemic corticosteroids. - Patients in which the largest diameter of the wheal induced by the positive control was < 3 mm. - Patients in which the largest diameter of the wheal induced by the negative control was = 3 mm. - Pregnancy, dermographism, atopic dermatitis (locally at the test site), urticaria. - Patients who suffer disease in which the use of adrenaline is not allowed. - Patients with any severe psychiatric disease. For the patients CH+: • Patients that received or are treated with immunotherapy with an allergenic extract of birch pollen and/or with allergen extracts with known cross-reactivity to birch pollen (Corylus avellana, Quercus verrucosa, Fagus sylvatica, Castanea satavia, Carpinus betelus and Alnus glutinosa). For the patients CH-: - Patients sensitized to pollen with demonstrated cross-reactivity with the pollen of Betula verrucosa. These pollen included Corylus avellana, Quercus verrucosa, Fagus sylvatica, Castanea satavia, Carpinus betelus and Alnus glutinosa.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
10 HEP/mL Betula verrucosa allergen extract
The investigational product contained 10 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
25 HEP/mL Betula verrucosa allergen extract
The investigational product contained 25 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
50 HEP/mL Betula verrucosa allergen extract
The investigational product contained 50 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
100 HEP/mL Betula verrucosa allergen extract
The investigational product contained 100 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.

Locations

Country Name City State
Spain Hospital Lucus Augusti Lugo Galicia

Sponsors (1)

Lead Sponsor Collaborator
Inmunotek S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity for 100 HEP/mL Sensitivity for 100 HEP/mL concentration of the pollen of Betula verrucosa allergen extract used in skin prick test.
It is the proportion of positives that are correctly identified by the test.
Sensitivity: True positives/Total disease
1 hour
Primary Sensitivity for 50 HEP/mL Sensitivity for 50 HEP/mL concentration of the pollen of Betula verrucosa allergen extract used in skin prick test.
It is the proportion of positives that are correctly identified by the test.
Sensitivity: True positives/Total disease
1 hour
Primary Sensitivity for 25 HEP/mL Sensitivity for 25 HEP/mL concentration of the pollen of Betula verrucosa allergen extract used in skin prick test.
It is the proportion of positives that are correctly identified by the test.
Sensitivity: True positives/Total disease
1 hour
Primary Sensitivity for 10 HEP/mL Sensitivity for 10 HEP/mL concentration of the pollen of Betula verrucosa allergen extract used in skin prick test.
It is the proportion of positives that are correctly identified by the test.
Sensitivity: True positives/Total disease
1 hour
Primary Specificity for 100 HEP/mL Specificity for 100 HEP/mL concentrations of the pollen of Betula verrucosa allergen extract used in skin prick test.
It is the proportion of negatives that are correctly identified by the test.
Specificity: True negatives/Total no disease.
1 hour
Primary Specificity for 50 HEP/mL Specificity for 50 HEP/mL concentrations of the pollen of Betula verrucosa allergen extract used in skin prick test.
It is the proportion of negatives that are correctly identified by the test.
Specificity: True negatives/Total no disease.
1 hour
Primary Specificity for 25 HEP/mL Specificity for 25 HEP/mL concentrations of the pollen of Betula verrucosa allergen extract used in skin prick test.
It is the proportion of negatives that are correctly identified by the test.
Specificity: True negatives/Total no disease.
1 hour
Primary Specificity for 10 HEP/mL Specificity for 10 HEP/mL concentrations of the pollen of Betula verrucosa allergen extract used in skin prick test.
It is the proportion of negatives that are correctly identified by the test.
Specificity: True negatives/Total no disease.
1 hour
See also
  Status Clinical Trial Phase
Recruiting NCT03663933 - Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation Phase 2
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Recruiting NCT04339777 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Phase 2
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT01441076 - Anakinra for Behcet s Disease Phase 1/Phase 2
Completed NCT01472263 - Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Phase 3
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Suspended NCT04642066 - Cold Water Immersion and Atherosclerosis, Inflammation, Fat Accumulation and Lipid Profile Parameters N/A
Completed NCT02294552 - Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT Phase 2
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Completed NCT04103099 - Impact of HLNatural Immune Supplement on Colds N/A
Recruiting NCT03344094 - Mechanism of Action of Ocrelizumab in Multiple Sclerosis N/A
Active, not recruiting NCT05445284 - Group Education Trial to Improve Transition for Parents of Adolescents With T1D N/A
Recruiting NCT06104111 - Epigenetic Memory of Vitamin D Supplementation Phase 1
Not yet recruiting NCT05616117 - Next-generation Effects of Vitamin D Supplementation in Pregnancy
Completed NCT01490177 - Single Center Food Allergy Oral Immunotherapy Study Phase 1
Completed NCT01510626 - Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center Phase 1
Completed NCT03922087 - No-worry Baby Project
Completed NCT03688074 - Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE) Phase 2